Cognitive impairment and dementia: a new emerging complication of type 2 diabetes—The diabetologist’s perspective

Acta Diabetologica

Volumn 54, Issue 5, 2017, Pages 417-424

  Simó, Rafael ^a,b   Ciudin, Andreea ^a,b   Simó Servat, Olga ^a,b   Hernández, Cristina ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Alzheimer s disease; Cognitive impairment; Dementia; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN DEGLUDEC; INSULIN GLARGINE; LONG ACTING INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL RESEARCH; COGNITIVE DEFECT; DEMENTIA; DEMENTIA ASSESSMENT; DIABETIC MICROANGIOPATHY; DIABETOLOGIST; EARLY DIAGNOSIS; ELECTRORETINOGRAPHY; ENDOCRINOLOGIST; GLYCEMIC CONTROL; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; INFLAMMATION; NERVE DEGENERATION; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DEGENERATION; RETINAL NEURODEGENERATION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; AGING; ANIMAL; COGNITIVE DYSFUNCTION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; METABOLISM; PHYSIOLOGY;

AGING; ALZHEIMER DISEASE; ANIMALS; COGNITIVE DYSFUNCTION; DEMENTIA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN; OXIDATIVE STRESS;

EID: 85013078291     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-017-0970-5     Document Type: Article

References (47)

1. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74
2. Kopf D, Frölich L (2009) Risk of incident alzheimer’s disease in diabetic patients: a systematic review of prospective trials. J Alzheimer Dis 16:677–685
3. Guariguata L, Nolan T, Beagley J, Linnenkamp U, Jacqmain O (2014) International Diabetes Federation diabetes atlas. International Diabetes Federation, Brussels
4. Thies W, Bleiler L, Alzheimer’s Association (2013) Alzheimer’s disease facts and figures. Alzheimer Dement 9:208–245
5. Koekkoek P, Kappelle LJ, van den Berg E, Rutten GEH, Biessels GJ (2015) Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol 14:329–340
6. Wang KC, Woung LC, Tsai MT, Liu CC, Su YH, Li CY (2012) Risk of alzheimer’s disease in relation to diabetes: a population-based cohort study. Neuroepidemiology 38:237–244
7. Huang CC, Chung CM, Leu HB et al (2014) Diabetes mellitus and the risk of alzheimer’s disease: a nationwide population-based study. PLoS One 9:e87095
8. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L (2009) Uncontrolled diabetes increases the risk of alzheimer’s disease: a population-based cohort study. Diabetologia 52:1031–1039
9. Tuligenga RH, Dugravot A, Tabák AG et al (2014) Midlife type 2 diabetes and poor glycemic control as risk factors for cognitive decline in early old age: a post hoc analysis of the Whitehall cohort study. Lancet Diabetes Endocrinol 2:228–235
10. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2009) Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58:71–77
11. Tolppanen AM, Lavikainen P, Solomon A et al (2013) History of medically treated diabetes and risk of alzheimer disease in a nationwide case-control study. Diabetes Care 36:2015–2019
12. De Felice FG, Ferreira ST (2014) Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to alzheimer disease. Diabetes 63:2262–2272
13. Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM (2016) Diabetes and alzheimer’s disease crosstalk. Neurosci Biobehav Rev 64:272–287
14. Whitmer RA, Kater AJ, Yaffe K, Quesenberry CP, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301:1565–1572
15. Feinkohl I, Aung PP, Keller M et al (2014) Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 37:507–515
16. Koekkoek PS, Janssen J, Kooistra M et al (2016) Case-finding for cognitive impairment among people with type 2 diabetes in primary care using test your memory and self-administered gerocognitive examination questionnaires: the Cog-ID study. Diabet Med 33:812–819
17. Exalto LG, Biessels GJ, Karter AJ et al (2013) Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol 1:183–190
18. Sullivan MD, Katon WJ, Lovato LC et al (2013) Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. JAMA Psychiatry 70:1041–1047
19. Biessels GJ, Reijmer YD (2014) Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes 63:2244–2252
20. Wisse LE, de Bresser J, Geerlings MI et al (2014) Global brain atrophy but not hippocampal atrophy is related to type 2 diabetes. J Neurol Sci 344:32–36
21. De Flores R, La Joie R, Chételat G (2015) Structural imaging of hippocampal subfields in healthy aging and alzheimer’s disease. Neuroscience 309:29–50
22. Biessels GJ, Reagan LP (2015) Hippocampal insulin resistance and cognitive dysfunction. Nat Rev Neurosci 16:660–671
23. Willette AA, Xu G, Johnson SC et al (2013) Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care 36:443–449
24. Raffield LM, Cox AJ, Freedman BI et al (2016) Analysis of the relationships between type 2 diabetes status, glycemic control, and neuroimaging measures in the diabetes heart study mind. Acta Diabetol 53:439–447
25. Hugenschmidt CE, Lovato JF, Ambrosius WT et al (2014) The cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care 37:3244–3252
26. Exalto LG, Biessels GJ, Karter AJ, Huang ES, Quesenberry CP, Whitmer RA (2014) Severe diabetic retinal disease and dementia risk in type 2 diabetes. J Alzheimer Dis 42(Suppl 3):S109–S117
27. de Bresser J, Reijmer YD, van der Exalto E et al (2010) Microvascular determinants of cognitive decline and brain volume change in elderly patients with type 2 diabetes. Dement Geriatr Cogn Disord 30:381–386
28. Barzilay JI, Lovato JF, Murray AM et al (2013) Albuminuria and cognitive decline in people with diabetes and normal renal function. Clin J Am Soc Nephrol 8:1907–1914
29. Lin CH, Sheu WHH (2013) Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med 273:102–110
30. Mattishent K, Loke YK (2016) Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab 18(2):135–141
31. Zhang Z, Lovato J, Battapady H et al (2014) Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial. Diabetes Care 37(12):3279–3285
32. Rizzo MR, Marfella R, Barbieri M et al (2010) Relationship between daily acute glucose fluctuations and cognitive performance among type 2 diabetic patients. Diabetes Care 33:2169–2174
33. Rizzo MR, Barbieri M, Boccardi V, Angellotti E, Marfella R, Paolisso G (2014) Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 69:1122–1131
34. Marciani E, Pomati S, Ramolfo P et al (2013) Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in alzheimer’s disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 54:5953–5958
35. Frost S, Kanagasingam Y, Macaulay L, Koronyo-Hamaoui M, Koronyo Y, Biggs D (2014) Retinal amyloid fluorescence imaging predicts cerebral amyloid burden and alzheimer’s disease. Alzheimer Dement 10:234–235
36. Simó R, Hernández C, European consortium for the early treatment of diabetic retinopathy (EUROCONDOR) (2014) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 25:23–33
37. Trento M, Durando O, Lavecchia S et al (2016) Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial. Endocrine. doi:10.1007/s12020-016-1097-0
38. Trento M, Charrier L, Salassa M et al (2016) Cognitive function may be a predictor of retinopathy progression in patients with type 2 diabetes. Eur J Ophthalmol. doi:10.5301/ejo.5000885
39. American Diabetes Association (2013) Clinical practice recommendations. Diabetes Care 36(Suppl 1):S3
40. Nicolucci A, Pintaudi B, Rossi MC et al (2015) The social burden of hypoglycemia in the elderly. Acta Diabetol 52:677–685
41. Hölscher C (2014) Insulin, incretins and other growth factors as potential novel treatments for alzheimer’s and parkinson’s diseases. Biochem Soc Trans 42:593–599
42. Hernández C, Bogdanov P, Corraliza L et al (2016) Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 65:172–187
43. Heneka MT, Fink A, Doblhammer G (2015) Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 78(2):284–294
44. Galimberti D, Scarpini E (2017) Pioglitazone for the treatment of alzheimer’s disease. Expert Opin Investig Drugs 26(1):97–101
45. Risner ME, Saunders AM, Altman JF et al (2006) Rosiglitazone in alzheimer’s disease study group. Pharmacogenomics J. 6(4):246–254
46. Chen Y, Zhang J, Zhang B, Gong CX (2016) Targeting insulin signaling for the treatment of alzheimer’s disease. Curr Top Med Chem 16:485–492
47. Claxton A, Baker LD, Hanson A et al (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage alzheimer’s disease dementia. J Alzheimer Dis 44:897–906